Mobic

Mobic is a brand name of meloxicam, approved by the FDA in the following formulation(s):

MOBIC (meloxicam - suspension; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: June 1, 2004
  
  Strength(s): 7.5MG/5ML ^[RLD]

MOBIC (meloxicam - tablet; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: April 13, 2000
  
  Strength(s): 7.5MG ^[AB]


• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: August 23, 2000
  
  Strength(s): 15MG ^[RLD][AB]

Has a generic version of Mobic been approved?

A generic version of Mobic has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Mobic and have been approved by the FDA:

meloxicam tablet; oral

• 
  Manufacturer: APOTEX INC
  
  Approval date: July 20, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: October 2, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: BEIJING DOUBLE CRANE
  
  Approval date: December 14, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: BRECKENRIDGE PHARM
  
  Approval date: July 19, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: CARACO
  
  Approval date: July 19, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: CARLSBAD
  
  Approval date: December 7, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: COREPHARMA
  
  Approval date: July 19, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: DR REDDYS LABS INC
  
  Approval date: July 25, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: GLENMARK GENERICS
  
  Approval date: July 19, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: LUPIN PHARMS
  
  Approval date: July 19, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: July 19, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: July 20, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: PURACAP PHARM
  
  Approval date: July 19, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: STRIDES ARCOLAB LTD
  
  Approval date: May 13, 2009
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: TARO
  
  Approval date: November 7, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: July 19, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: UNICHEM
  
  Approval date: December 20, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: July 19, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]


• 
  Manufacturer: ZYDUS PHARMS USA
  
  Approval date: July 19, 2006
  
  Strength(s): 15MG ^[AB], 7.5MG ^[AB]

Note: No generic formulation of the following product is available.

• meloxicam - suspension; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mobic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Oral suspension of pharmaceutical substance
  Patent 6,184,220
  Issued: February 6, 2001
  Inventor(s): Turck; Dietrich & Schmelmer; Veit
  Assignee(s): Boehringer Ingelheim Pharma KG
  The present invention relates to orally administered suspensions of pharmaceutical active substances of the NSAID type, particularly the antirheumatic agent Meloxicam, which are stabilized by the addition of small amounts of highly dispersed silicon dioxide using high shear forces and adding small amounts of hydrophilic polymers to form a three-dimensional siloid structure, and a process for the preparation thereof.
  
  Patent expiration dates:
  
  
  • March 25, 2019
    
    ✓ 
    Drug product
  
  
  
  • September 25, 2019
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 11, 2012 - ORPHAN DRUG EXCLUSIVITY
  
  
  • February 11, 2013 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Mobic Consumer Information (Drugs.com)
• Mobic Consumer Information (Wolters Kluwer)
• Mobic Suspension Consumer Information (Wolters Kluwer)
• Mobic Consumer Information (Cerner Multum)
• Mobic Advanced Consumer Information (Micromedex)
• Mobic AHFS DI Monographs (ASHP)
• Meloxicam Consumer Information (Wolters Kluwer)
• Meloxicam Suspension Consumer Information (Wolters Kluwer)
• Meloxicam Consumer Information (Cerner Multum)
• Meloxicam Advanced Consumer Information (Micromedex)
• Meloxicam AHFS DI Monographs (ASHP)